Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation

Authors

Matthew J. Roberts
Renee S. Richards
Clement W.K. Chow
Marion Buck
John Yaxley
Martin F. Lavin
Horst Joachim Schirra
Robert A. Gardiner, Edith Cowan University

Document Type

Journal Article

Publisher

Elsevier

School

Exercise Medicine Research Institute

RAS ID

26410

Comments

Roberts, M. J., Richards, R. S., Chow, C. W., Buck, M., Yaxley, J., Lavin, M. F., ... & Gardiner, R. A. (2017). Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation. Prostate International, 5(4), 149-157.

https://doi.org/10.1016/j.prnil.2017.03.005

Abstract

Background:

Diagnosis and monitoring of localized prostate cancer requires discovery and validation of noninvasive biomarkers. Nuclear magnetic resonance (NMR)-based metabolomics of seminal plasma reportedly improves diagnostic accuracy, but requires validation in a high-risk clinical cohort.

Materials and methods:

Seminal plasma samples of 151 men being investigated for prostate cancer were analyzed with ¹H-NMR spectroscopy. After adjustment for buffer (add-to-subtract) and endogenous enzyme influence on metabolites, metabolite profiling was performed with multivariate statistical analysis (principal components analysis, partial least squares) and targeted quantitation.

Results:

Seminal plasma metabolites best predicted low- and intermediate-risk prostate cancer with differences observed between these groups and benign samples. Lipids/lipoproteins dominated spectra of high grade samples with less metabolite contributions. Overall prostate cancer prediction using previously described metabolites was not validated.

Conclusion:

Metabolomics of seminal plasma in vitro may assist urologists with diagnosis and monitoring of either low or intermediate grade prostate cancer. Less clinical benefit may be observed for high-risk patients. Further investigation in active surveillance cohorts, and/or in combination with in vivo magnetic resonance spectroscopic imaging may further optimize localized prostate cancer outcomes.

DOI

10.1016/j.prnil.2017.03.005

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.